High quality early phase clinical trials are important to identify safe and efficacious interventions for further study. For these trials, rapid recruitment and late toxicity onset can cause suboptimal outcomes. My research aims to address these challenges by developing new dose-finding trial designs that modify when study participants can be included in the trial and the dose-response modeling. These designs are evaluated via simulation study against established designs as well as using actual trial data.